Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
Kurreck A, Geissler M, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Stintzing S, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Modest DP. Kurreck A, et al. Among authors: seidensticker m. J Cancer Res Clin Oncol. 2020 Oct;146(10):2681-2691. doi: 10.1007/s00432-020-03257-z. Epub 2020 May 24. J Cancer Res Clin Oncol. 2020. PMID: 32449003 Free PMC article. Clinical Trial.
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M. Modest DP, et al. Among authors: seidensticker m. J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609637 Clinical Trial.
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O, Schütte K, Kupčinskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M. Öcal O, et al. Among authors: seidensticker m, seidensticker r. J Cancer Res Clin Oncol. 2022 Feb;148(2):475-485. doi: 10.1007/s00432-021-03627-1. Epub 2021 Apr 14. J Cancer Res Clin Oncol. 2022. PMID: 33855585 Free PMC article. Clinical Trial.
Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board.
Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, Rühlmann K, Flach M, Biro D, von Bergwelt-Baildon M, Holch J, Herold T, von Baumgarten L, Greif PA, Jeremias I, Wuerstlein R, Casuscelli J, Spitzweg C, Seidensticker M, Renz B, Corradini S, Baumeister P, Goni E, Tufman A, Jung A, Kumbrink J, Kirchner T, Klauschen F, Metzeler KH, Heinemann V, Westphalen CB. Heinrich K, et al. Among authors: seidensticker m. J Cancer Res Clin Oncol. 2023 May;149(5):1905-1915. doi: 10.1007/s00432-022-04165-0. Epub 2022 Jul 7. J Cancer Res Clin Oncol. 2023. PMID: 35796778 Free PMC article. Review.
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Dorman K, Zhang D, Heinrich K, Reeh L, Weiss L, Haas M, Beyer G, Rössler D, Goni E, Renz BW, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Dorman K, et al. Among authors: seidensticker m. Target Oncol. 2023 Mar;18(2):257-267. doi: 10.1007/s11523-023-00950-0. Epub 2023 Feb 28. Target Oncol. 2023. PMID: 36853374 Free PMC article.
Chances, challenges and outcomes of patients with complex bilobar colorectal liver metastases approached by a combined multimodal therapy with liver resection and local ablative therapy.
Drefs M, Schoenberg MB, Schiergens TS, Albertsmeier M, Andrassy J, Angele MK, Westphalen CB, Seidensticker M, Werner J, Guba MO. Drefs M, et al. Among authors: seidensticker m. J Surg Oncol. 2021 Jun;123(7):1578-1591. doi: 10.1002/jso.26443. Epub 2021 Mar 8. J Surg Oncol. 2021. PMID: 33684241
Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease.
Mehrens D, Unterrainer M, Corradini S, Niyazi M, Manapov F, Westphalen CB, Froelich MF, Wildgruber M, Seidensticker M, Ricke J, Rübenthaler J, Kunz WG. Mehrens D, et al. Among authors: seidensticker m. Front Oncol. 2021 Jun 15;11:667993. doi: 10.3389/fonc.2021.667993. eCollection 2021. Front Oncol. 2021. PMID: 34211842 Free PMC article.
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
Öcal O, Rössler D, Gasbarrini A, Berg T, Klümpen HJ, Bargellini I, Peynircioglu B, van Delden O, Schulz C, Schütte K, Iezzi R, Pech M, Malfertheiner P, Sangro B, Ricke J, Seidensticker M. Öcal O, et al. Among authors: seidensticker m. J Cancer Res Clin Oncol. 2022 Sep;148(9):2487-2496. doi: 10.1007/s00432-021-03803-3. Epub 2021 Sep 20. J Cancer Res Clin Oncol. 2022. PMID: 34541612 Free PMC article. Clinical Trial.
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Öcal O, et al. Among authors: seidensticker m. Cancer Imaging. 2022 Jan 4;22(1):1. doi: 10.1186/s40644-021-00439-x. Cancer Imaging. 2022. PMID: 34983668 Free PMC article.
204 results